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Letters to the Editor 
HALOPERIDOL DECANOATE : ROUTE OF AD-
MINISTRATION 
Sir, 
Haloperidol decafloate (HPL-D) is a useful 
depot neuroleptic on several counts : it has a dura-
tion of action of 4-6 weeks, there is no dumping ef-
fect associated with its administration, and the ad-
verse effects milligram for milligram are fewer and 
milder than those observed with the oral form of 
haloperidol (Beresford and Ward, 1987, Glazer and 
Kane, 1992). 
HPL-D requires to be administered by deep 
intramuscular injection; subcutaneous administra-
tion may be associated with the development of in-
jection site reactions (Hamann et al., 1990). In low 
doses, intramuscular administration into the deltoid 
is feasible and convenient. In high doses, however, 
the larger volume of drug to be administered ne-
cessitates injection into the gluteus. 
This is where the problem arises. Disposable 
syringes in India usually have an approximately one 
inch needle length. Disposable 21 gauge needles, 
required for use with HPL-D, are generally of the 
same length. Consttutional and behavioural factors, 
more in women than in men, usually result in the 
presence of gluteal fat that is over an inch or two in 
thickness in the average Indian patient. In conse-
quence, it is likely that despite gluteal compression 
during injection, few Indian patients truly receive 
deep intramuscular HPL-D when the drug is injected 
into the buttock, in fact, it is possible that many pa-
tients are actually receiving the injection in subcu-
taneous fat. 
No reports of injection site reaction with HPL-
D have appeared in the Indian scientific press. Is 
this because of under-reporting or might subcuta-
neous HPL-D be less harmful than earlier 
believed ? 
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STRESS, DEPRESSION AND GENOMIC CHANGE 
Sir, 
Deregulation of hypothalamo- pituitary ad-
renal axis (HPA) is one of the oldest and most con-
sistent findings in depression. It is now generally 
accepted that stressful life events and chronic diffi-
culties can trigger the onset of depression in pre-
disposed individuals. Enough is known about the 
central control of HPA function and its response to 
stress in the neurobiology of triggering the depres-
sion. The stress induces hypercortisolaemia which 
triggers depression by inducing genomic change. 
There are two types of corticoid receptors in brain 
tissue - type I and type II receptors (Reul & De Kloet, 
1986). Under basal conditions Cortisol has very high 
affinity with 80% occupancy of type I receptors 
whereas type II receptors are occupied and acti-
vated only during stress (Ratka, 1989). Further, hip-
pocampus is the most vulnerable site for the 
neurotoxic action of glucocorticoids The 
glucocorticoid recepters are predominandy present 
in hippocampal area. Of late, in vivo hippocampal 
atrophy assessed using magnetic resonance imag-
ing has been correlated with plasma Cortisol levels 
in depression (Axelson et al., 1993) A related but 
astonishing fact is that all hormones with weH de-
fined effects on mood (estrogen, progesterone, 
glucocorticoids and thyroxine) have intraceRuar re-
ceptors whereas most other hormones act through 
membrane receptors. More surprising than this is 
that these intracellular receptors have two 
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